CCL2 and acute myeloid leukemia: Disease-stabilizing low-toxicity treatment is now tried in AML, and a recent study investigated the cytokine profiles in patients receiving valproic acid + ATRA (including the chemokines CCL2/3/4/5/11 and CXCL5/8/10/11) [39].